Form 4: Natera Executive Sells Shares for Tax Obligations

Natera's President of Clinical Diagnostics, Solomon Moshkevich, sold 292 shares of common stock at $187.95 per share to cover tax obligations from RSU vesting.

Summary

• Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NTRA), reported a sale of common stock.
• The transaction involved 292 shares of Natera common stock.
• The shares were sold at a price of $187.95 per share, totaling approximately $54,871.40.
• The sale was executed on October 21, 2025.
• Following this transaction, Moshkevich beneficially owns 117,267 shares of Natera common stock.
• The sale was made to satisfy tax withholding and remittance obligations related to the vesting of Restricted Stock Units (RSUs).
• The transaction was conducted pursuant to a Rule 10b5-1(c) written plan, which was established on January 28, 2022.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale by an insider to cover tax obligations associated with RSU vesting, executed under a pre-established Rule 10b5-1(c) plan. It does not reflect a change in management's outlook on the company or a strategic divestment.

Positives

• The sale was pre-planned under a Rule 10b5-1(c) plan, indicating a structured approach to managing equity and tax liabilities rather than a discretionary sale based on market timing.
• The transaction is for tax purposes, which is a routine and expected event for executives receiving equity compensation.

Negatives

• No inherent negatives are identified as the sale is for tax purposes and not a discretionary divestment.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

Not applicable, as this Form 4 filing reports a past insider transaction and does not contain forward-looking statements or guidance.

Management Comments

• The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs.
• The sale was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.

Industry Context

This is a routine insider transaction common across all industries for executives who receive equity compensation. It reflects the standard practice of selling a portion of vested shares to cover tax liabilities, rather than a strategic divestment based on company performance or outlook.

Comparison to Industry Standards

• This type of transaction, a sale of shares to cover tax obligations upon RSU vesting, is a standard practice for executives across publicly traded companies globally.
• It aligns with typical equity compensation and tax management strategies, and does not indicate any deviation from industry norms or specific company performance issues.
• For example, executives at companies like Illumina (ILMN) or Guardant Health (GH) with similar equity compensation structures frequently report similar tax-related sales.

Stakeholder Impact

• Shareholders: Minimal direct impact. The sale is a small percentage of the executive's holdings and is for tax purposes, not a signal of lack of confidence.
• Employees: No direct impact.
• Customers/Suppliers/Creditors: No direct impact.

Next Steps

• No specific future actions or milestones are mentioned in this Form 4 filing.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary sale of shares by an executive to cover tax obligations arising from RSU vesting, executed under a pre-established Rule 10b5-1(c) plan. Such transactions are common and do not typically signal a change in the company's fundamentals or the executive's long-term view. Therefore, this filing alone does not provide a basis for changing an investment position, and a 'hold' recommendation is appropriate.

Keywords

Natera, NTRA, Form 4, insider transaction, stock sale, RSU, tax withholding, Solomon Moshkevich, Rule 10b5-1, equity compensation